{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T02:51:31Z","timestamp":1775875891969,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Densitometry"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jocd.2018.03.004","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T00:19:23Z","timestamp":1529453963000},"page":"20-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Glucocorticoid-Induced Osteoporosis: Management Challenges in Older Patients"],"prefix":"10.1016","volume":"22","author":[{"given":"Robert A.","family":"Adler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocd.2018.03.004_bib0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMcp1012926","article-title":"Clinical practice: glucocorticoid-induced bone disease","volume":"365","author":"Weinstein","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2018.03.004_bib0015","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"van Staa","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2018.03.004_bib0020","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jocd.2018.03.004_bib0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/jbmr.5650030117","article-title":"Effect of short-term glucocorticoids on serum osteocalcin in healthy young men","volume":"3","author":"Godschalk","year":"1988","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2018.03.004_bib0030","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/ard.2004.035022","article-title":"Changes of cartilage and bone markers after intra-articular glucocorticoid treatment with and without post-injection rest in patients with rheumatoid arthritis","volume":"64","author":"Weitoft","year":"2005","journal-title":"Ann Rheum Dise"},{"key":"10.1016\/j.jocd.2018.03.004_bib0035","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/acr.23279","article-title":"2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jocd.2018.03.004_bib0040","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00198-013-2519-y","article-title":"Use of a performance algorithm improves utilization of vertebral fracture assessment in clinical practice","volume":"25","author":"Schousboe","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2018.03.004_bib0045","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00198-015-3078-1","article-title":"The impact of glucocorticoid therapy on trabecular bone score in older women","volume":"26","author":"Paggiosi","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2018.03.004_bib0050","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.39726","article-title":"Trabecular bone score in patients with chronic glucocorticoid therapy-induced osteoporosis treated with alendronate or teriparatide","volume":"68","author":"Saag","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jocd.2018.03.004_bib0055","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","article-title":"Oral corticosteroids and fracture risk","volume":"39","author":"van Staa","year":"2000","journal-title":"Rheumatology"},{"key":"10.1016\/j.jocd.2018.03.004_bib0060","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1007\/s00198-016-3646-z","article-title":"Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis","volume":"27","author":"Balasubramanian","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2018.03.004_bib0065","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11914-016-0308-1","article-title":"The skeletal effects of inhaled glucocorticoids","volume":"14","author":"Sutter","year":"2016","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.jocd.2018.03.004_bib0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2018.03.004_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2018.03.004_bib0080","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2018.03.004_bib0085","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jbmr.233","article-title":"Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996\u20132007","volume":"26","author":"Wang","year":"2011","journal-title":"J Bone Miner Re"},{"key":"10.1016\/j.jocd.2018.03.004_bib0090","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","article-title":"A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis","volume":"23","author":"Lekamsawam","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2018.03.004_bib0095","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"67","author":"Wallach","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jocd.2018.03.004_bib0100","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","article-title":"Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids","volume":"44","author":"Adachi","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jocd.2018.03.004_bib0105","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00198-012-2060-4","article-title":"Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in practice","volume":"24","author":"Thomas","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2018.03.004_bib0110","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2017.8040","article-title":"Association between alendronate use and hip fracture risk in older patients using oral prednisolone","volume":"318","author":"Axelsson","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2018.03.004_bib0115","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicenter, double-blind, double-dummy, randomized controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jocd.2018.03.004_bib0120","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jbmr.1870","article-title":"Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs Trial","volume":"28","author":"Gluer","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2018.03.004_bib0125","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jocd.2018.03.004_bib0130","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00198-014-3022-9","article-title":"Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis","volume":"26","author":"Overman","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2018.03.004_bib0135","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-SWITCH Study): extension of a randomized controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jocd.2018.03.004_bib0140","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicenter, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jocd.2018.03.004_bib0145","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2018.03.004_bib0150","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s12020-016-1146-8","article-title":"Glucocorticoid-induced osteoporosis: pathophysiological role of GH\/IGF-I and PTH\/Vitamin D axes, treatment options, and guidelines","volume":"54","author":"Mazziotti","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.jocd.2018.03.004_bib0155","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1007\/s00198-006-0149-3","article-title":"Glucocorticoid-induced osteoporosis program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year","volume":"17","author":"Newman","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2018.03.004_bib0160","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s00198-011-1534-0","article-title":"Fracture liaison services for evaluation and management of patients with osteoporotic fractures: a cost-effectiveness evaluation based on data collected over 8 years of service provision","volume":"22","author":"McLellan","year":"2011","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.jocd.2018.03.004_bib0165","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.2106\/JBJS.L.00223","article-title":"Fracture liaison service: impact on subsequent nonvertebral fracture incidence and mortality","volume":"96","author":"Huntjens","year":"2014","journal-title":"J Bone Joint Surg Am"}],"container-title":["Journal of Clinical Densitometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695018300179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695018300179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:41:39Z","timestamp":1761082899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094695018300179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1094695018300179"],"URL":"https:\/\/doi.org\/10.1016\/j.jocd.2018.03.004","relation":{},"ISSN":["1094-6950"],"issn-type":[{"value":"1094-6950","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucocorticoid-Induced Osteoporosis: Management Challenges in Older Patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Densitometry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocd.2018.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of The International Society for Clinical Densitometry.","name":"copyright","label":"Copyright"}]}}